Swiss pharma giant Novartis bets on a breast cancer blockbuster as sales rise

Novartis reported robust Q2 core operating income growth of 21% to $5.93 billion, slightly exceeding estimates, while net sales rose 11% (cc) to $14.05 billion, just shy of forecasts. The company is strategically mitigating the upcoming mid-2025 U.S. patent expiry for its top-selling Entresto, which recently saw an injunction request rejected, by accelerating new growth drivers. CEO Vas Narasimhan highlighted Kisqali, its breast cancer treatment, as the next blockbuster, with Q2 sales surging 64% globally (100% in U.S.), alongside other promising pipeline assets like Pluvicto and Scemblix. Novartis upgraded its full-year core operating income growth forecast to "low teens" and announced a $10 billion share buyback, underscoring confidence in its long-term portfolio strength despite impending patent challenges.

Analysis

Novartis demonstrated robust operational performance in its second quarter, with adjusted core operating income rising 21% to $5.93 billion, exceeding analyst expectations. While net sales grew 11% to $14.05 billion, this figure fell slightly short of consensus estimates. The central theme of the report is the company's strategic pivot to mitigate the impending U.S. patent expiry for its leading heart failure drug, Entresto, which is anticipated to face generic competition by mid-2025. This risk was recently amplified by a U.S. court's rejection of a preliminary injunction against a generic manufacturer. In response, management is aggressively promoting its new growth drivers, designating the breast cancer treatment Kisqali as its next blockbuster. Kisqali's sales surged 64% on a constant currency basis in Q2, including 100% growth in the U.S., validating its commercial momentum. Further pipeline strength is cited from Pluvicto and Scemblix, both of which are on a blockbuster trajectory. The company's confidence is underscored by an upgraded full-year forecast for core operating income growth to "low teens" and the announcement of a new $10 billion share buyback program, signaling a belief that its growth portfolio can successfully navigate the transition away from Entresto.

Key Decisions for Investors

• Investors should focus on the sales trajectory of Kisqali, Pluvicto, and Scemblix as the primary metric for gauging the success of Novartis's strategy to offset the inevitable revenue decline from Entresto.
• Closely monitor legal and regulatory developments concerning Entresto's patent litigation, as any change to the mid-2025 generic entry timeline represents the most significant near-term risk to earnings forecasts.
• The upgraded full-year operating income guidance and the $10 billion share buyback should be viewed as strong indicators of management's confidence, potentially providing a valuation floor as the company navigates its patent cliff.